Genesis Wealth Advisors LLC Invests $2.55 Million in Johnson & Johnson (NYSE:JNJ)

Genesis Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 17,630 shares of the company’s stock, valued at approximately $2,550,000. Johnson & Johnson makes up about 2.2% of Genesis Wealth Advisors LLC’s investment portfolio, making the stock its 16th largest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. B&D White Capital Company LLC lifted its position in shares of Johnson & Johnson by 82.7% during the 4th quarter. B&D White Capital Company LLC now owns 7,400 shares of the company’s stock worth $1,070,000 after buying an additional 3,350 shares in the last quarter. Birchcreek Wealth Management LLC increased its position in shares of Johnson & Johnson by 10.9% during the fourth quarter. Birchcreek Wealth Management LLC now owns 5,347 shares of the company’s stock valued at $773,000 after acquiring an additional 526 shares during the last quarter. Partners Wealth Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $323,000. South Dakota Investment Council boosted its position in Johnson & Johnson by 1.1% in the fourth quarter. South Dakota Investment Council now owns 229,647 shares of the company’s stock worth $33,212,000 after purchasing an additional 2,500 shares during the last quarter. Finally, World Equity Group Inc. grew its stake in Johnson & Johnson by 99.2% in the 4th quarter. World Equity Group Inc. now owns 24,872 shares of the company’s stock valued at $3,582,000 after purchasing an additional 12,384 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Guggenheim lifted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Finally, Bank of America reduced their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Down 2.0 %

JNJ stock opened at $162.75 on Thursday. The stock has a 50-day simple moving average of $150.08 and a two-hundred day simple moving average of $155.97. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The firm has a market capitalization of $391.83 billion, a PE ratio of 24.47, a PEG ratio of 2.56 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the company earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.05%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.